

**Alexandra S. Potter**  
**CURRICULUM VITAE**

Position: Associate Professor  
Department of Psychiatry

Address: Clinical Neuroscience Research Unit  
Department of Psychiatry  
The Robert Larner, M.D. College of Medicine  
University of Vermont  
1 South Prospect St., Arnold 6  
Burlington, VT 05405  
Voice: (802) 847-6955  
email: Alexandra.Potter@uvm.edu

**EDUCATION**

<b>Year</b>	<b>Institution</b>	<b>Degree</b>	<b>Major/Accolades</b>
1996–2003	University of Vermont	PhD	Clinical Psychology
2001	University of Vermont	Internship	Clinical Psychology
1986–1990	University of Vermont	BA	Psychology Cum Laude

**DISSERTATION**

The effects of acute nicotine administration in adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD)

Thesis Advisor: Paul Newhouse, MD

**LICENSES, CERTIFICATION**

2007–Present Psychologist Doctorate, Vermont (License #: 048.0000900)

**FACULTY POSITIONS HELD**

<b>Years</b>	<b>Institution</b>	<b>Academic Title</b>	<b>Department</b>
2018–Present	University of Vermont, Burlington	Associate Professor	Psychiatry
2018–Present	University of Vermont, Burlington	Associate Professor	Psychological Science
2010–Present	UVM Medical Center, Burlington	Clinical Psychologist	Mental Health Services
2008–2018	University of Vermont, Burlington	Assistant Professor	Psychological Science
2005–2018	University of Vermont, Burlington	Assistant Professor	Psychiatry

**OTHER POSITIONS AND MAJOR ADMINISTRATIVE POSITIONS HELD**

<b>Years</b>	<b>Location/Program Name</b>	<b>Role</b>
--------------	------------------------------	-------------

1997–1998	Vermont Interdisciplinary Leadership and Education for Healthcare Professionals (VT-ILEHP)	Psychology Trainee
1997–2002	Family Therapy Team, UVM	Family Therapist
1999	The May Center for Child Development, Chatham, MA	Summer Trainee
2000–2003	Behavior Therapy & Psychotherapy Center	Psychology Trainee
2003–2005	University of Vermont, Psychiatry	Postdoctoral Associate
2003–Present	Behavior Therapy & Psychotherapy Center	Clinician/Supervisor
2005–Present	Graduate College	Faculty Member
2005–Present	Neuroscience Graduate Program	Faculty Member
2012–Present	Clinical Neuroscience Research Unit Department of Psychiatry	Co-Director

### HONORS AND AWARDS

Year	Name of Award
2020	Gender Equity Outstanding Achievement in Medicine and Science, Nominee
2013	B.F. Skinner Invited Lecture, Association for Behavior Analysis International (ABAI)
2011	Inducted into the UVM Inventor Hall of Fame
2010–Present	Ambassador, National Institutes of Health Loan Repayment Program
2005	Travel Award Fellow, Society of Biological Psychiatry
2003	Graduate Student Travel Fellowship, University of Vermont Graduate College
1996	Phi Beta Kappa, Member
1990	John Dewey Award for excellence in undergraduate research, University of Vermont

### KEYWORDS/AREAS OF INTEREST

Nicotine, acetylcholine, cholinergic, adolescent, addiction, development, ADHD, stop signal task, inattention, fMRI

### SUMMARY OF PROFESSIONAL ACTIVITIES- OVERALL

**SUMMARY OF PROFESSIONAL ACTIVITIES – OVERALL** I am an Associate Professor on the Research Track in the Department of Psychiatry. Since joining the faculty in 2003, I have obtained over \$17 million in funding as PI from the National Institutes of Health, published over 60 manuscripts in peer-reviewed scientific journals (h-index=25), successfully mentored scholars at all levels of training, and have leadership roles serving my scientific communities.

I am a Site PI for the Adolescent Brain Cognitive Development (ABCD) study; a 21 site, 10-year longitudinal study of over 11,000 adolescents, funded by the NIH (<https://abcdstudy.org>). The UVM cohort has 575 families, with retention at 3-years >97%, with 98% data completion. I lead two ABCD Consortium-level Workgroups (Mental Health, and Gender Identity and Sexual Health). Workgroups consist of Nationally recognized domain experts, and recommend developmentally appropriate, reliable and valid assessment strategies for use in ABCD each year. I am a Site PI for the Healthy Brain Child Development (HBCD) Study; a new NIH funded consortium that will enroll and follow approximately 7,500 women in the second trimester of pregnancy, and follow their children longitudinally for 10

years. This study is modeled after ABCD, with 25 data collection sites across the country. I am Co-Chair of the Neurocognition and Language workgroup for HBCD. At UVM, I have also developed strong collaborations and currently am a Co-Investigator on 4 R01 level grants. My local *service* includes service on the Medical Sciences IRB. I joined the IRB in 2008, was Associate Chair from 2016-2018 and have served as Chair since 2018. I serve on the safety subcommittee and the Policy & Procedure Committees, overseen by the UVM Vice President for Research. My *teaching* similarly centers around research and includes providing lectures on the ethical principles of Human Subjects research, and mentoring all levels of students. I am a PI on a recently awarded Supplement the UVM Site for ABCD, to implement a project titled “Scientific training in addiction research techniques (START) for gifted future investigators from historically underrepresented and underserved backgrounds. This project will leverage UVM’s strength as a data collection site for ABCD to create this mentorship program in collaboration with researchers at the University of South Florida. I provide clinical supervision to psychology graduate student and have been on the Medical Staff of the University of Vermont Medical Center since 2010.

**SUMMARY OF ACCOMPLISHMENTS**

- Internationally recognized expert in nicotinic acetylcholine receptor function and cognition.
- Internationally recognized expert on adolescent brain development and addiction.
- Continuously funded by the NIH since 2005 with over \$17 million awarded as PI.
- Strong peer reviewed publication record with 60+ papers (h-index=25).
- Chair of the UVM Medical Sciences IRB.
- Mentor to graduate students, post-doctoral scholars, and junior faculty.
- Chair of two Assessment Workgroups for the National ABCD Study, and one Workgroup for the National HBCD Study.
- Expert on ethical issues as evidenced by selection to two Data Safety Monitoring Boards – one for a study of suicide risk and the other for a Phase I drug development trial.

**PROFESSIONAL SERVICE**

---

DEPARTMENTAL SERVICE

<b>Years</b>	<b>Department</b>	<b>Committee</b>	<b>Role</b>
2010–2014	Psychiatry	Research Day	Co-Coordinator
2010–2015	Neuroscience	Graduate Admissions	Member
2015–Present	Psychiatry	Space	Member
2015–Present	Neuroscience	Summer Neuroscience Undergraduate Research Fellowship Advisory Board	Member

COLLEGE SERVICES

<b>Years</b>	<b>Service Committee</b>	<b>Role</b>
2012–2014	College of Medicine Tissue Sharing Committee	Member
2015-2018	College of Medicine Research Committee (Grant	Ad-Hoc Member

	Review Committee)	
2017	Larner College of Medicine Health Services Pilot Grant Awards Review Committee	Member
2017	Northern New England Clinical & Translational Science Pilot Grants Review Committee	Ad-Hoc Member
2017-Present	Medical Student Research Awards Committee	Member

#### MEDICAL CENTER SERVICE

2019	MRI Physicist Search Committee (clinical position)	Member
------	--	--------

#### UNIVERSITY SERVICE

<b>Years</b>	<b>Service Committee</b>	<b>Role</b>
2008-Present	UVM MRI Research Center Advisory Board	Member
2008–2016	UVM Medical Sciences IRB	Member
2016	Director of UVM Research Protections Office Search Committee	Member
2014-Present	UVM Medical Sciences IRB Policy and Procedures Committee	Member
2016-2018	UVM Medical Sciences IRB	Associate Chair
2016-Present	UVM Medical Science IRB Safety Committee	Member
2016-Present	UVM Medical Sciences IRB Policy & Procedures	Member
2017	UVM Executive Director of Research Administration Search Committee	Member
2017-Present	Data Safety and Monitoring Board for NIH SBIR Trial “Systematic Expert Risk Assessment for Suicide (SERAST™)”	Member
2018	UVM REACH grant review committee	Member
2018-Present	UVM Medical Sciences IRB	Chair
2019	Computer Science tenure-track faculty in “Computational Intelligence” search committee	Member

#### NATIONAL SERVICE – RESEARCH RELATED

<b>Years</b>	<b>Service Committee</b>	<b>Role</b>
2015-Present	ABCD Council of Investigators	Member
2016-Present	ABCD Workgroup: Gender Identity and Sexual Health	Chair
2016-Present	ABCD Workgroup: Mental Health	Chair
2017-Present	Safety Management Committee – VU319 Phase I Trial	Member

#### GOVERNMENT SERVICE

<b>Years</b>	<b>Service Committee</b>	<b>Role</b>
2008	NIDA, Member Conflict Special Emphasis Panel	Member
2008	NIDA – Imaging Science Awards for Rapid Transition (I/START) Review Panel	Ad Hoc Member
2009	NIDA – Special Emphasis Panel - Behavioral Pharmacology and Genetics: Translating and Targeting Individual Differences	Member

2009	NIDA – Imaging Science Awards for Rapid Transition (I/START) Review Panel	Ad Hoc Member
2010	NIDA – Imaging Science Awards for Rapid Transition (I/START) Review Panel	Ad Hoc Member (3 panels)
2012–2018	VT Tobacco Evaluation and Review Board (VTERB)	Governor Appointed Member
2012-2018	Evaluation Committee - VTERB	Chair
2012–2014	VT Dept. of Health – Healthy Communities Grant Program Review Committee	Member
2016	VT Dept. Education – School Based Smoking Prevention Grant Review Committee	Member
2017	NIDA – Cutting Edge Basic Research Award (CEBRA) Review Panel	Ad Hoc Member
2017	NICHHD – Biobehavioral and Behavioral Sciences Study Section	Ad Hoc Member

### SOCIETY MEMBERSHIPS

<b>Years</b>	<b>Society</b>
2005 – Present	Society for Neuroscience
2006 – 2013	Society for Research on Nicotine and Tobacco
2007 – 2014	Society of Biological Psychiatry
2013 – Present	Organization of Human Brain Mapping

### SERVICE TO PROFESSIONAL PUBLICATIONS

<b>Years</b>	<b>Journal/Publication/Board</b>
2005-Present	<i>I have served as an ad-hoc reviewer for:</i> <i>Addictive Behavior, American Journal of Psychiatry (JAMA Psychiatry), Archives of General Psychiatry, Archives of Pediatric and Adolescent Medicine, Biological Psychiatry, Child and Adolescent Psychiatry and Mental Health, Child Development, Child Neuropsychology, CNS Spectrums, Cognitive Therapy and Research, Experimental and Clinical Psychopharmacology, Expert Opinion on Investigational Drugs, Hippocampus, JAMA Pediatrics, Neuroepidemiology, Neuropharmacology, Neuropsychopharmacology, Nicotine and Tobacco Research, Pediatric Research, Pharmacology, Biochemistry and Behavior, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Psychiatry Research, Psychological Medicine, Psychology of Addictive Behaviors, Psychopharmacology, Schizophrenia Bulletin</i>

### PUBLIC SERVICE

<b>Years</b>	<b>Service Role</b>
2018	Public Education Talk – (attendance approx.. 250) The Adolescent Brain
2018	Presenter – Community Rounds for Larner College of Medicine
2013	Key Note Address for Vermont High School Brain Bee
2013	Workshop presented to the New England Survivors of Torture and Trauma Working Group titled “Neuropsychological Assessment: Application in Refugee Communities”
2008	Public Education Talk (attendance approx. 125) titled “Living, Loving and

2004 Communicating – Adult ADHD and Relationships”  
University of Ottawa's University Medical Research Fund (Department  
Of Psychiatry) Grant Reviewer

### SUMMARY OF SERVICE ACTIVITIES

My service activities at all levels (Departmental, College, University, and Government) have focused around my primary responsibility of research. This is exemplified by my service as a member, Associate Chair, and now Chair of the UVM Medical Sciences IRB. This committee oversees the review of all medical research protocols involving human subjects. As Chair of this committee, I oversee the monthly review meetings, communicate with investigators about ethical/regulatory issues, and serve on the Safety subcommittee (which reviews adverse events and conducts non-compliance inquiries when needed), and the Policy & Procedures committee.

At the State level, I review grant applications to State of Vermont Agencies and served as a Governor's appointee to the Vermont Tobacco Evaluation and Review Board (VTERB) from 2012 – 2017. I was Chair of the Evaluation Committee from 2015-2017. VTERB oversaw independent evaluation of Vermont's Tobacco Control Program, and the Evaluation Committee oversaw the external evaluation contract. As a VTERB member provided legislative testimony on the value of evaluation research in governmental decision making. My national research service includes being an ad-hoc reviewer for NIH study sections and serving on a Safety Management Committee for a Phase I drug development trial. This committee is charged with reviewing safety data from each drug dose level and making a recommendation to continue or stop the trial. I have National leadership roles on the ABCD study including serving as a Chair of both the Mental Health and Gender Identity and Sexual Health Workgroups; and was selected to Co-Chair the Neurocognition and Language workgroup for the National HBCD Study. These positions allow me to participate in important design decisions for these landmark longitudinal studies of development. I have served as an ad-hoc reviewer for 27 journals including flagship journals in my field (JAMA Pediatrics, JAMA Psychiatry, Child Development).

### TEACHING

#### FORMAL SCHEDULED CLASSES

Year	Course Title	Course		Hours	Number of Learners	Learner Level
		R	E			
2008	Basic Science of Neurological Disease: Autism		X	3	~20	G,Res
2008	Assessment of Cognition and Personality	X		3	~8	Res
2010, 2011	Introductory Neuroscience Seminar	X		1.5	~6	Res
2010, 2011	Advanced Neuroscience Seminar	X		1.5	~6	Res
2012	Clinical Neurobiology and Neuropharmacology Seminar	X		1.5	~8	Res
2013-Present – annually	Responsible Conduct of Research: Human Subjects	X		1.5	~20	G,Res
2013, 2015, 2017	Neuroscience Series I: Neurobiology of Attention	X		1.5	~8	Res
2014, 2016	Neuroscience Series II: Neurobiology of Impulsivity	X		1.5	~8	Res

2014, 2017	Introduction to fMRI (design and analysis)		X	8.0	30	U,G
2015, 2016	Developmental Neurobiology: ADHD	X		3.0	~12	G
2017, 2018, 2020, 2021	Neurobiology of Addiction	X		1.5	~25	G

R-required; E-elective; Hours-approx. per semester; G-graduate studies

### CURRICULUM DEVELOPMENT - none

### POSTGRADUATE AND OTHER COURSES – none

### UNDERGRADUATE/MEDICAL STUDENTS

Dates	Name	Program School	Role	Current Position
2009–2010	Jessica Scharf	Undergraduate	Honors Thesis Co-Advisor	Counseling, Private Practice, Burlington VT
2010	Khadar Kakuma	Undergraduate	Summer Research Mentor	Unknown
2011	Samuel Akinyeye	Undergraduate	Summer Research Mentor	Resident, Baylor College of Medicine
2012-2016	Eli Sepkowitz	Post-baccalaureate	Research Mentor	Medical Student, SUNY Upstate
2013	Janina Bowen	Undergraduate	Research Mentor for credit	Ph.D. Student, Univ. of Colorado
2014	Samin Shebab	Medical Student	Research Rotation Mentor	UVM College of Medicine
2014	Heleni Ramirez	Undergraduate	Summer Research Mentor	California Polytechnic
2014	Irene Soulos	Undergraduate	Summer Research Mentor	Mount Holyoke College
2014-2016	Ellen Wixted	Undergraduate	Honors Thesis Advisor	Ph.D. Student, U of Michigan
2014–2016	Irene Sue	Undergraduate	Honors Thesis Advisor	Medical Student, UVM LCOM
2015	Sofia Neira	Undergraduate	Summer Research Mentor	University of Central Florida
2016	Dana Beach	Undergraduate	Summer Research Mentor	Wesleyan University of Ohio
2017	Daniel Lee	Undergraduate	Summer Research Mentor	Unknown
2018	Vincent Nocera	Medical Student	Summer Research Mentor	Medical Student, UVM LCOM

### PREDOCTORAL STUDENTS SUPERVISED OR MENTORED

Dates	Name	Program School	Role	Current Position
2005 - 2011	Ryan, Katherine K.	Doctoral, UVM Clinical Psychology	PhD Advisor	Clinical Psychologist, Maine Medical Center
2009 - 2014	Mazzulla, Emily, C	Doctoral, UVM Clinical Psychology	PhD Advisor	Assistant Professor, Marquette Univ.
2010-2017	Schaubhut, Geoffrey	MS – Neuroscience, UVM; Doctoral Clinical Psychology, UVM	MS and PhD Advisor	Post-Doctoral Scholar, Oregon Health and Sciences University
2018-Present	Hannah Loso	Doctoral, UVM Clinical Psychology	PhD Advisor	Student
2018-2020	Zoe Hulce	MS, Pharmacology, UVM	Thesis Advisor	Research Specialist

### DISSERTATION/THESIS COMMITTEE MEMBERSHIP

Date	Name	Program	Role	Current Position
2007	Neil Kirkpatrick	PhD	Member	Clinical Director, Behavior Therapy Center of Tacoma, Tacoma WA

2007	Stephanie Anne Nelson	PhD	Member	Private Practice, Bellevue, WA
2009	Daniel Cassidy	PhD	Member	Clinical Psychologist, Lackland Air Force Base
2010	Nina Madore	MS	Chair	Unknown
2011	Julia McQuade	PhD	Member	Assistant Professor, Amherst College
2011	Meghan Tomb	PhD	Member	Assistant Professor, Columbia University School of Medicine
2012	Rachel Cooper	MS	Chair	Unknown
2013	Simone Otto	PhD	Member	Postdoctoral Fellow, NIEHS
2014	KC Olds	MS	Member	Unknown
2015	Kimberly Albert	PhD	Member	Postdoctoral Fellow, Vanderbilt
2017	Philip Spechler	PhD	Member	Postdoctoral Fellow, LIBR
2018	Nicholas D'Alberto	PhD	Member	Assistant Professor, UVM LCOM
2019	Merelise Ametti	MS	Member	PhD Student, UVM Psychology
2019	Doris Ogden	PhD	Member	Research Specialist, UVM

#### POSTDOCTORAL FELLOWS AND RESIDENTS DIRECTLY SUPERVISED OR MENTORED

<b>Date</b>	<b>Name</b>	<b>Program School</b>	<b>Role</b>	<b>Current Position</b>
2015-2018	Matthew Albaugh	Postdoctoral Associate	Co-mentor	UVM Assistant Professor–Psychiatry
2015-2018	Catherine Orr	Postdoctoral Associate	Co-mentor	Lecturer, Swinburne University
2015-2019	Bader Charani	Postdoctoral Associate	Co-mentor	UVM Assistant Professor–Psychiatry
2018-2021	Shana Adise	Postdoctoral Associate	Co-mentor	UVM Assistant Professor–Psychiatry
2019-Present	Max Owens	Postdoctoral Associate	Co-mentor	Post-doctoral Fellow

INFORMAL TEACHING - none

#### FACULTY MENTORED

<b>Dates</b>	<b>Name</b>	<b>Position while Mentored</b>	<b>Role</b>	<b>Current Position</b>
2010-2014	James Boyd, MD	Assistant Professor	Mentor (Research Award from Parkinson's Study Group)	Associate Professor of Neurological Sciences, UVM
2018-Present	Matthew Albaugh, Ph.D.	Assistant Professor	Mentor	Assistant Professor, Psychiatry, UVM
2019-Present	Bader Charani	Assistant Professor	Mentor	Assistant Professor, Psychiatry, UVM

OTHER VISITING FACULTY SUPERVISED - none

TEACHING AIDS - none

TEACHING AWARDS AND NOMINATIONS - none

#### SUMMARY OF TEACHING ACTIVITIES



As an Associate Professor on the Research Scholar Pathway, my primary teaching occurs outside of the classroom, mentoring students in my laboratory. I have mentored 5 Ph.D. students, and served on 14 thesis committees, and mentored undergraduates during the academic year, and during the summer through the NSF/NIH funded program “Summer Neuroscience Undergraduate Research Fellowship” (SNURF) program. I actively mentor post-doctoral scholars (3 currently) and Jr. faculty (4 currently). I lecture in courses including annual teaching on the ethics of Human Subjects Research to graduate students and medical Residents and lectures on the neurobiology of addiction, attention and impulsivity, and the measurement of executive function. I am a PI on a recently awarded Supplement the UVM Site for ABCD, to implement a project titled “Scientific training in addiction research techniques (START) for gifted future investigators from historically underrepresented and underserved backgrounds. This project is a collaboration with researchers at the University of South Florida, and leverages UVM’s strength as a data collection site for ABCD to create this unique mentorship program.

## **RESEARCH AND SCHOLARLY ACTIVITIES**

---

### **RESEARCH AWARDS AND GRANTS**

#### **Ongoing Research Support**

1U01DA055354-01 Sponsor: NIH/NIDA	Potter, Garavan (MPI)	9/2021 – 6/2026 Role: PI (Multiple)
--------------------------------------	-----------------------	--

#### **The Healthy Brain and Child Development National Consortium**

The goal of this project is to characterize brain development from the perinatal period through early childhood, and to understand factors affecting variability in development and how neurodevelopment relates to cognitive, behavioral, social, and emotional function. This is a 10-year longitudinal study that will enroll approximately 10,000 women in the second trimester of pregnancy (with over enrollment of those who use substances during pregnancy).

3U01DA051039-02S1	Potter, Garavan (MPI)	9/2021 – 3/2022
-------------------	-----------------------	-----------------

#### **Scientific training in addiction research techniques (START) for gifted future investigators from historically underrepresented and underserved backgrounds**

This is a supplement to the UVM grant for data collection for the ABCD Study. This supplement creates a pilot project to incorporate training in the collection and analysis of ABCD Study data for under-represented scholars. START will increase access to this rich dataset and provide a year-long, hands-on mentored experience for 12 Fellows (4 Faculty, 4 Post-Doctoral, 4 Graduate Students).

U01DA051039	Potter, Garavan (MPI)	4/2020 - 3/2027 Role: PI (Multiple)
-------------	-----------------------	--

#### **Adolescent Brains Cognitive Development (ABCD) Research Project**

This is the second funding cycle, providing 7 years of support for data collection in the ABCD study. The study is a large-scale (>11,000 children) longitudinal study of child/adolescent development. The overarching goal is to use cutting-edge technology to determine how childhood experiences interact with each other and with a child’s changing biology to affect brain development and—ultimately—social, behavioral, academic, health, and other outcomes.

Annual Direct Costs (ADC) \$1,600,000

P20GM103644-01A1

Higgins (PI)

09/2013 – 09/2023

Sponsor: NIGMS

Role: Co-Investigator

Vermont Center on Behavior and Health

This COBRE grant forms the Vermont Center on Behavior and Health which investigates relationships between personal behaviors and risk for chronic disease and premature death. I am a Co-Investigator in the Behavioral Economics and Intervention Sciences Core where my role includes developing and implementing a common battery of neuropsychological tests measuring executive function administered across COBRE research projects.

ADC:\$1,156,814

R34DA050283

Potter, Heil, Garavan (MPI)

09/2019 – 03/2022

NIDA/NIMH

Role: PI (Multiple)

3 of 4, Investigation of Opioid Exposure and Neurodevelopment (iOPEN)

This Phase I planning grant will develop and test recruitment and retention strategies, implement a standardized multi-modal MRI protocol, and evaluate data processing and statistical considerations to maximize data quality in the Phase II HEALthy Brain and Child Development Study.

ADC \$225,000

R34DA050283-Supplement

Potter, Heil, Garavan (MPI)

04/2020 – 03/2022

NIDA/NIMH

Role: PI (Multiple)

Longitudinal evaluation of the impact of the COVID-19 pandemic on high-risk new and expectant mothers

This is an Administrative Supplement to examine the impact of the COVID-19 pandemic on the experience of pregnancy and parenting. Evaluations are harmonized across 8 sites, each conducting assessment of social isolation, stress, impacts of the pandemic, attachment, and child development.

ADC: \$100,000

R01 AG066159

Dumas

09/2019 - 08/2024

NIH/NIA

Role: Co-Investigator

Health of the cholinergic system and risk for Alzheimer's Disease in postmenopausal women

The goal of this project is to understand how cholinergic system functioning during aging affects cognition in postmenopausal women. This work will inform risk factors for developing Alzheimer's Disease.

ADC \$900,000

R33HL143305

Gaalema (PI)

08/2018-07/2023

NIH/NHLBI

Role: Co-Investigator

Improving Participation in Cardiac Rehabilitation among Lower-Socioeconomic Status Patients: Efficacy of Early Case Management and Financial Incentives

ADC: \$480.234

R01 AG050716-01A1

Dumas (PI)

5/2016 - 5/2022

Sponsor: NIH/NIA

Role: Co-Investigator

The Nicotinic System and Cognitive Aging

The goal of this project is to understand how the nicotinic system is involved in and responsible for the cognitive changes seen during normal cognitive aging.

ADC \$300,000

**Completed Research Support**

U24DA041147

Brown, Jernigan

4/2016 – 4/2020

NIH/NIDA

ABCD-USA Consortium Coordinating Center

The goals of this project are to coordinate the multi-site longitudinal study on the effects of substance use on the adolescent brain and cognition. I have a sub-contract to develop a reliable and valid dimensional measure of gender for adolescents

Role: Subcontract PI

ADC: \$250,000

U01DA041148

Fair, Feldstein Ewing, Garavan, Nagel, Potter

10/2013-10/2020

NIH/NIDA

Adolescent Brains Cognitive Development (ABCD) Research Project

The ABCD study is a large-scale (10,000 children) longitudinal study (10 years) of child/adolescent cognitive development (<http://abcdstudy.org>). The overarching goal is to use cutting-edge technology to determine how childhood experiences interact with each other and with a child's changing biology to affect brain development and—ultimately—social, behavioral, academic, health, and other outcomes. This study is being conducted at 19 sites across the country (funded through U01 cooperative study applications). The award to UVM and Oregon Health Sciences University (our partner sites) is for both data collection and the development of state of the art analytic methods for predicting child outcomes from baseline brain imaging and phenotypic data.

Role: UVM PI (MPI)

ADC: \$1,602,506

K23 MH079216

Potter

4/2009 – 03/2015

NIMH

Neurobiology of Cognitive Deficits in Neurodevelopmental Disorders

This Career Development Award provides research and career development training in using methods including pharmacologic manipulations, functional magnetic resonance imaging, and cognitive testing for understanding the neurobiology of cognitive deficits in neurodevelopmental disorders.

Role: PI

Young Investigator

Potter

7/2009 – 6/2014

Award, NARSAD

Nicotinic Cholinergic Contributions to Social Information Processing in Prodromal Schizophrenia

This study uses nicotinic cholinergic blockade during functional magnetic resonance imaging (fMRI) to assess the role of the cholinergic system in emotional face recognition in subjects with prodromal schizophrenia and healthy controls.

Role: PI

Mentored Clinical

Boyd (PI)

7/2010 – 6/2014

Research Award, PSG

Nicotine Treatment of Impulsivity in Parkinson's disease: A Pilot Study

This award provides research mentoring to Dr. Boyd in the use of cognitive paradigms to measure changes in fundamental cognitive operations that are related to clinical symptoms. This pilot study will test the hypothesis that treatment with chronic nicotine will alleviate clinical levels of impulsivity and compulsivity (i.e. gambling, shopping, hypersexual behavior) in patients with Parkinson's disease.

Role: Mentor

NIH Loan Repayment Program, NIH      Potter      2004 –2007, 2008 – 2013

The NIH Clinical Research Loan Repayment Program is a competitive program, in which a portion of the applicant's student loans are paid by NIH for scientists doing research with human subjects. The research projects of the applicant are evaluated in determining the awards.

Role: Recipient

RC1 DA0288173      Nishi      9/2009 – 8/2011  
NIH/NIDA

Adolescent brains, nicotine and endogenous prototoxins

This NIDA Challenge Grant uses a multi-disciplinary translational research team to investigate links between endogenous prototoxins, expression of nicotinic acetylcholine receptors in the brain, and adolescent health behavior including cigarette smoking and impulsivity.

Role: Co-Investigator

R03 DA023460      Potter      4/2008 – 3/2010  
NIH/NIDA

The Functional Neuroanatomy of Acute Nicotinic Modulation of Impulsivity in Women

This grant funds a study examining the cortical circuitry involved in changes in impulsivity associated with both nicotine administration and nicotine withdrawal in female cigarette smokers and non-smokers.

Role: PI

Investigator Initiated      Newhouse, Potter      5/2008 – 12/2009  
Targacept Inc.

The Effect of TC1734 on Behavioral Inhibition in Attention-Deficit/Hyperactivity Disorder (ADHD)

This is an investigator initiated grant to investigate the effects a novel nicotinic agonist on cognition and symptoms of adult ADHD.

Role: PI

New Research Initiatives      Potter      1/2006 – 12/2008  
UVM CoM

Correlates of Impulsivity in Young Adults

The goal of this grant is to examine the relationship between self-report and laboratory measures of impulsivity and how they relate to psychiatric diagnoses and substance abuse.

Role: PI

RO3 MH073573-01A1      Potter      9/2005 – 9/2007  
NIMH

Cholinergic Effects on Inhibition and Delay in ADHD

This project is designed to examine the acute effects of nicotine compared to methylphenidate and placebo on behavioral inhibition and delay aversion in young adults with ADHD.

Role: PI

R21 MH069670      Bucci      12/2003 – 12/2006  
NIMH/NIDA



4. Newhouse, P. A., **Potter**, A., Corwin, J., & Lenox, R. (1994b). Modeling the nicotinic receptor loss in dementia using the nicotinic antagonist mecamylamine: Effects on human cognitive functioning. *Drug development research*, 31(1), 71-79. IF=4.36
5. Newhouse, P., & **Potter**, A. (1996). The effects of nicotinic agents on cognition and behavior in Alzheimer's disease. *Drug development research*, 38, 278-289. IF=4.36
6. Newhouse, P. A., **Potter**, A., & Levin, E. D. (1997). Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. *Drugs Aging*, 11(3), 206-228. doi:10.2165/00002512-199711030-00005 IF=3.92
7. **Potter**, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999). Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease. *Psychopharmacology (Berl)*, 142(4), 334-342. doi:10.1007/s002130050897 IF=4.53
8. Newhouse, P. A., **Potter**, A., Kelton, M., & Corwin, J. (2001). Nicotinic treatment of Alzheimer's disease. *Biol Psychiatry*, 49(3), 268-278. doi:10.1016/s0006-3223(00)01069-6 IF=13.38
9. Newhouse, P. A., **Potter**, A., Kelton, M., & Corwin, J. (2001). Nicotinic treatment of Alzheimer's disease. *Biological psychiatry*, 49(3), 268-278. IF=13.38
10. Newhouse, P., Singh, A., & **Potter**, A. (2004). Nicotine and nicotinic receptor involvement in neuropsychiatric disorders. *Curr Top Med Chem*, 4(3), 267-282. doi:10.2174/1568026043451401 IF=4.00
11. Newhouse, P. A., **Potter**, A., & Singh, A. (2004). Effects of nicotinic stimulation on cognitive performance. *Curr Opin Pharmacol*, 4(1), 36-46. doi:10.1016/j.coph.2003.11.001 IF=5.55
12. **Potter**, A. S., & Newhouse, P. A. (2004). Effects of acute nicotine administration on behavioral inhibition in adolescents with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl)*, 176(2), 182-194. doi:10.1007/s00213-004-1874-y IF=4.53
13. Singh, A., **Potter**, A., & Newhouse, P. (2004). Nicotinic acetylcholine receptor system and neuropsychiatric disorders. *IDrugs*, 7(12), 1096-1103.
14. MacLeod, J. E., **Potter**, A. S., Simoni, M. K., & Bucci, D. J. (2006). Nicotine administration enhances conditioned inhibition in rats. *Eur J Pharmacol*, 551(1-3), 76-79. doi:10.1016/j.ejphar.2006.08.082 IF=4.43
15. **Potter**, A. S., Newhouse, P. A., & Bucci, D. J. (2006). Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/hyperactivity disorder? *Behav Brain Res*, 175(2), 201-211. doi:10.1016/j.bbr.2006.09.015 IF=3.33
16. **Potter**, A. S., & Newhouse, P. A. (2008). Acute nicotine improves cognitive deficits in young adults with attention-deficit/hyperactivity disorder. *Pharmacol Biochem Behav*, 88(4), 407-417. doi:10.1016/j.pbb.2007.09.014 IF=3.53
17. **Potter**, A. S., Ryan, K. K., & Newhouse, P. A. (2009). Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD). *Hum Psychopharmacol*, 24(4), 309-317. doi:10.1002/hup.1026 IF=1.67

18. Newhouse, P. A., **Potter**, A. S., Dumas, J. A., & Thiel, C. M. (2011). Functional brain imaging of nicotinic effects on higher cognitive processes. *Biochem Pharmacol*, *82*(8), 943-951. doi:10.1016/j.bcp.2011.06.008 IF=5.86
19. **Potter**, A. S., Bucci, D. J., & Newhouse, P. A. (2012). Manipulation of nicotinic acetylcholine receptors differentially affects behavioral inhibition in human subjects with and without disordered baseline impulsivity. *Psychopharmacology (Berl)*, *220*(2), 331-340. doi:10.1007/s00213-011-2476-0 IF=4.53
20. \*Ryan, K. K., Dube, S. L., & **Potter**, A. S. (2013). Rate dependent effects of acute nicotine on risk taking in young adults are not related to ADHD diagnosis. *Pharmacol Biochem Behav*, *103*(3), 652-658. doi:10.1016/j.pbb.2012.11.005 IF=3.53
21. Jucaite, A., Ohd, J., **Potter**, A. S., Jaeger, J., Karlsson, P., Hannesdottir, K., . . . Paulsson, B. (2014). A randomized, double-blind, placebo-controlled crossover study of alpha4beta 2\* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder. *Psychopharmacology (Berl)*, *231*(6), 1251-1265. doi:10.1007/s00213-013-3116-7 IF=4.53
22. **Potter**, A. S. (2014). Smoking cessation in men and women. *Am J Psychiatry*, *171*(11), 1148-1150. doi:10.1176/appi.ajp.2014.14081032 IF=18.11
23. **Potter**, A. S., Dunbar, G., Mazzulla, E., Hosford, D., & Newhouse, P. A. (2014). AZD3480, a novel nicotinic receptor agonist, for the treatment of attention-deficit/hyperactivity disorder in adults. *Biol Psychiatry*, *75*(3), 207-214. doi:10.1016/j.biopsych.2013.06.002 IF=13.38
24. **Potter**, A. S., Schaubhut, G., & Shipman, M. (2014). Targeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to date. *CNS Drugs*, *28*(12), 1103-1113. doi:10.1007/s40263-014-0208-9 IF=5.75
25. \*Spechler, P. A., Chaarani, B., Hudson, K. E., **Potter**, A., Foxe, J. J., & Garavan, H. (2016). Response inhibition and addiction medicine: from use to abstinence. *Prog Brain Res*, *223*, 143-164. doi:10.1016/bs.pbr.2015.07.024
26. \*Albaugh, M. D., Orr, C., Chaarani, B., Althoff, R. R., Allgaier, N., D'Alberto, N., . . . **Potter**, A. S. (2017). Inattention and Reaction Time Variability Are Linked to Ventromedial Prefrontal Volume in Adolescents. *Biol Psychiatry*, *82*(9), 660-668. doi:10.1016/j.biopsych.2017.01.003 IF=13.36
27. \*D'Alberto, N., Funnell, M., **Potter**, A., & Garavan, H. (2017). A split-brain case study on the hemispheric lateralization of inhibitory control. *Neuropsychologia*, *99*, 24-29. doi:10.1016/j.neuropsychologia.2017.02.017 IF=3.14
28. Barch, D. M., Albaugh, M. D., Avenevoli, S., Chang, L., Clark, D. B., Glantz, M. D., . . . Sher, K. J. (2018). Demographic, physical and mental health assessments in the adolescent brain and cognitive development study: Rationale and description. *Dev Cogn Neurosci*, *32*, 55-66. doi:10.1016/j.dcn.2017.10.010 IF=6.46
  - This manuscript presents the mental health assessments used in ABCD, I Co-Chair the mental health workgroup and contributed to the conceptualization, writing, and editing of this manuscript.

29. \*D'Alberto, N., Chaarani, B., Orr, C. A., Spechler, P. A., Albaugh, M. D., Allgaier, N., . . . Garavan, H. (2018). Individual differences in stop-related activity are inflated by the adaptive algorithm in the stop signal task. *Hum Brain Mapp*, *39*(8), 3263-3276. doi:10.1002/hbm.24075
30. Garavan, H., Bartsch, H., Conway, K., Decastro, A., Goldstein, R. Z., Heeringa, S., . . . Zahs, D. (2018). Recruiting the ABCD sample: Design considerations and procedures. *Dev Cogn Neurosci*, *32*, 16-22. doi:10.1016/j.dcn.2018.04.004 IF=6.46
  - I am a site PI for the ABCD Study and my role was to participate in consortium-wide discussions and decisions about recruitment.
31. O'Halloran, L., Cao, Z., Ruddy, K., Jollans, L., Albaugh, M. D., Aleni, A., . . . Whelan, R. (2018). Neural circuitry underlying sustained attention in healthy adolescents and in ADHD symptomatology. *Neuroimage*, *169*, 395-406. doi:10.1016/j.neuroimage.2017.12.030 IF=6.56
32. \*Albaugh, M. D., Hudziak, J. J., Ing, A., Chaarani, B., Barker, E., Jia, T., . . . **Potter**, A. (2019). White matter microstructure is associated with hyperactive/inattentive symptomatology and polygenic risk for attention-deficit/hyperactivity disorder in a population-based sample of adolescents. *Neuropsychopharmacology*, *44*(9), 1597-1603. doi:10.1038/s41386-019-0383-y IF=7.85
33. \*Albaugh, M. D., Hudziak, J. J., Orr, C., Spechler, P. A., Chaarani, B., Mackey, S., . . . Consortium, I. (2019). Amygdalar reactivity is associated with prefrontal cortical thickness in a large population-based sample of adolescents. *PLoS One*, *14*(5), e0216152. doi:10.1371/journal.pone.0216152 IF=3.24
34. \*Albaugh, M. D., Ivanova, M., Chaarani, B., Orr, C., Allgaier, N., Althoff, R. R., . . . **Potter**, A. S. (2019). Ventromedial Prefrontal Volume in Adolescence Predicts Hyperactive/Inattentive Symptoms in Adulthood. *Cereb Cortex*, *29*(5), 1866-1874. doi:10.1093/cercor/bhy066 IF=6.11
35. \*Albaugh, M. D., & **Potter**, A. S. (2019). The ventromedial prefrontal cortex: a putative locus for trait inattention. *Neuropsychopharmacology*, *44*(1), 226-227. doi:10.1038/s41386-018-0193-7 IF=7.85
36. \*Charrani, B., Kan, K. J., Mackey, S., Spechler, P. A., **Potter**, A., Orr, C., . . . Consortium, I. (2019). Low Smoking Exposure, the Adolescent Brain, and the Modulating Role of CHRNA5 Polymorphisms. *Biol Psychiatry Cogn Neurosci Neuroimaging*, *4*(7), 672-679. doi:10.1016/j.bpsc.2019.02.006 IF=6.20
37. Gaalema, D. E., Dube, S., **Potter**, A., Elliott, R. J., Mahoney, K., Sigmon, S. C., . . . Ades, P. A. (2019). The effect of executive function on adherence with a cardiac secondary prevention program and its interaction with an incentive-based intervention. *Prev Med*, *128*, 105865. doi:10.1016/j.ypmed.2019.105865 IF=4.02
38. Hagler, D. J., Jr., Hatton, S., Cornejo, M. D., Makowski, C., Fair, D. A., Dick, A. S., . . . Dale, A. M. (2019). Image processing and analysis methods for the Adolescent Brain Cognitive Development Study. *Neuroimage*, *202*, 116091. doi:10.1016/j.neuroimage.2019.116091 IF=6.56
  - This manuscript presents the imaging methods used in the ABCD study, as a Site PI I participated in the conceptualization and implementation of these methods.



39. \*Orr, C., Spechler, P., Cao, Z., Albaugh, M., Chaarani, B., Mackey, S., . . . Garavan, H. (2019). Grey Matter Volume Differences Associated with Extremely Low Levels of Cannabis Use in Adolescence. *J Neurosci*, 39(10), 1817-1827. doi:10.1523/JNEUROSCI.3375-17.2018 IF=5.67
40. \*Spechler, P. A., Allgaier, N., Chaarani, B., Whelan, R., Watts, R., Orr, C., . . . Consortium, I. (2019). The initiation of cannabis use in adolescence is predicted by sex-specific psychosocial and neurobiological features. *Eur J Neurosci*, 50(3), 2346-2356. doi:10.1111/ejn.13989 IF=3.39
41. \*Charrani, B., Kan, K. J., Mackey, S., Spechler, P. A., **Potter**, A., Banaschewski, T., . . . Consortium, I. (2020). Neural Correlates of Adolescent Irritability and Its Comorbidity With Psychiatric Disorders. *J Am Acad Child Adolesc Psychiatry*, 59(12), 1371-1379. doi:10.1016/j.jaac.2019.11.028 IF=6.94
42. Dube, S. L., Sigmon, S., Althoff, R. R., Dittus, K., Gaalema, D. E., Ogden, D. E., . . . **Potter**, A. S. (2020). Association of self-reported executive function and mood with executive function task performance across adult populations. *Appl Neuropsychol Adult*, 1-12. doi:10.1080/23279095.2020.1794869 IF=1.49
43. Herting, M. M., Uban, K. A., Gonzalez, M. R., Baker, F. C., Kan, E. C., Thompson, W. K., . . . Sowell, E. R. (2020). Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. *Front Endocrinol (Lausanne)*, 11, 549928. doi:10.3389/fendo.2020.549928 IF=5.55
44. Laurent, J. S., Watts, R., Adise, S., Allgaier, N., Chaarani, B., Garavan, H., . . . Mackey, S. (2020). Associations Among Body Mass Index, Cortical Thickness, and Executive Function in Children. *JAMA Pediatr*, 174(2), 170-177. doi:10.1001/jamapediatrics.2019.4708 IF=16.20
45. \*Owens, M. M., Hyatt, C. S., Gray, J. C., Miller, J. D., Lynam, D. R., Hahn, S., . . . Garavan, H. (2020). Neuroanatomical correlates of impulsive traits in children aged 9 to 10. *J Abnorm Psychol*, 129(8), 831-844. doi:10.1037/abn0000627 IF=6.48
46. \*Owens, M. M., Yuan, D., Hahn, S., Albaugh, M., Allgaier, N., Chaarani, B., . . . Garavan, H. (2020). Investigation of Psychiatric and Neuropsychological Correlates of Default Mode Network and Dorsal Attention Network Anticorrelation in Children. *Cereb Cortex*, 30(12), 6083-6096. doi:10.1093/cercor/bhaa143 IF=6.11
47. \*Adise, S., Allgaier, N., Laurent, J., Hahn, S., Chaarani, B., Owens, M., . . . Garavan, H. P. (2021). Multimodal brain predictors of current weight and weight gain in children enrolled in the ABCD study (R). *Dev Cogn Neurosci*, 49, 100948. doi:10.1016/j.dcn.2021.100948 IF=6.46
48. \*Albaugh, M. D., Ottino-Gonzalez, J., Sidwell, A., Lepage, C., Juliano, A., Owens, M. M., . . . Rioux, P. (2021). Association of Cannabis Use During Adolescence With Neurodevelopment. *JAMA psychiatry*. IF=21.60
49. \*Charrani, B., Hahn, S., Allgaier, N., Adise, S., Owens, M. M., Juliano, A. C., ... & Rajapaske, N. (2021). Baseline brain function in the preadolescents of the ABCD Study. *Nature Neuroscience*, 1-11. IF=21.13

50. Dube, S., Ivanova, M., & **Potter**, A. (2021). "I Don't Understand": Who Is Missed When We Ask Early Adolescents, "Are You Transgender"? *Arch Sex Behav*, 50(3), 741-745. doi:10.1007/s10508-021-01986-x IF=4.51
51. Li, Y., Thompson, W. K., Reuter, C., Nillo, R., Jernigan, T., Dale, A., . . . Rauschecker, A. (2021). Rates of Incidental Findings in Brain Magnetic Resonance Imaging in Children. *JAMA neurology*, 78(5), 578-587. IF=18.3
52. \*Loso, H. M., Dube, S. L., Chaarani, B., Garavan, H., Albaugh, M., Ivanova, M., & **Potter**, A. (2021). Sex Differences in Psychopathology in a Large Cohort of Nine and Ten-Year-Olds. *Psychiatry Research*, 114026. IF=3.22
53. \*Owens, M. M., Allgaier, N., Hahn, S., Yuan, D., Albaugh, M., Adise, S., . . . Garavan, H. (2021a). Correction to: Multimethod investigation of the neurobiological basis of ADHD symptomatology in children aged 9-10: baseline data from the ABCD study. *Transl Psychiatry*, 11(1), 216. doi:10.1038/s41398-021-01320-y IF=5.90
54. \*Owens, M. M., Allgaier, N., Hahn, S., Yuan, D., Albaugh, M., Adise, S., . . . Garavan, H. (2021b). Multimethod investigation of the neurobiological basis of ADHD symptomatology in children aged 9-10: baseline data from the ABCD study. *Transl Psychiatry*, 11(1), 64. doi:10.1038/s41398-020-01192-8 IF=5.90
55. **Potter**, A. (2021). Commentary: Reply to 'Transgender and mental health' by Philip Graham. *J Child Psychol Psychiatry*. doi:10.1111/jcpp.13441 IF=8.89
56. **Potter**, A., Dube, S., Allgaier, N., Loso, H., Ivanova, M., Barrios, L. C., . . . Johns, M. M. (2021). Early adolescent gender diversity and mental health in the Adolescent Brain Cognitive Development study. *J Child Psychol Psychiatry*, 62(2), 171-179. doi:10.1111/jcpp.13248 IF=8.89
57. **Potter**, A. S., Owens, M. M., Albaugh, M., Garavan, H., Sher, K. J., Kaufman, J., & Barch, D. M. (2021). Obsessive-Compulsive Disorder in the Adolescent Brain Cognitive Development Study: Impact of Changes From DSM-IV to DSM-5. *J Am Acad Child Adolesc Psychiatry*, 60(4), 421-424. doi:10.1016/j.jaac.2020.07.904 IF=6.94
58. Price, M., Albaugh, M., Hahn, S., Juliano, A. C., Fani, N., Brier, Z. M. F., . . . Garavan, H. (2021). Examination of the association between exposure to childhood maltreatment and brain structure in young adults: a machine learning analysis. *Neuropsychopharmacology*. doi:10.1038/s41386-021-00987-7 IF=7.85
59. Silveri, M. M., Schuttenberg, E. M., Schmandt, K., Stein, E. R., Rieselbach, M. M., Sternberg, A., . . . **Potter, A.S.**, . . . & Boger, K. D. (2021). Clinical Outcomes Following Acute Residential Psychiatric Treatment in Transgender and Gender Diverse Adolescents. *JAMA Network Open*, 4(6), e2113637. IF=8.48
60. \*Kohlasch, K.L., Cioffred, L.A., Lenninger, C., Stewart, E., Vatalaro, T., Garavan, H., Graham, A., Heil, S.H., Krans, E.E., Robakis, T., Rommeli, A., Sullivan, E.L., Thomason, M.E., **Potter, A.** (2021) Factors associated with parent views about participation in infant MRI research provide guidance for the design of the Healthy Brain and Child Development (HBCD) study. *Developmental Cognitive Neuroscience*. 50, 100986. IF=6.46

61. DePietro, J, Mackiewicz Seghete, KL, Krans, EE, Snider, KE, Bower, R, Parker, K, Gullickson, J, **Potter**, AS, Garavan, H, Vatalaro, TC, Thomason, ME, Sullivan, EL, & Graham, AM (in press). Stakeholder perspectives on advancing understanding of prenatal opioid exposure and brain development from the iOPEN Consortium of the Healthy Brain and Cognitive Development Study. *Frontiers in Developmental Psychology*. *IF=2.99*
62. \*Owens, M. M., Potter, A., Hyatt, C. S., Albaugh, M., Thompson, W. K., Jernigan, T., ... **Potter, A.** & Garavan, H. (2021). Recalibrating expectations about effect size: A multi-method survey of effect sizes in the ABCD study. *Plos one*, 16(9), e0257535.
63. \*Owens, M. M., Hahn, S., Allgaier, N., MacKillop, J., Albaugh, M., Yuan, D., Juliano, A., **Potter, A.**, Garavan, H. (*in press*). One Year Predictions of Delayed Reward Discounting in the Adolescent Brain Cognitive Development Study. *Experimental and Clinical Psychopharmacology*.

#### Book Chapters

1. Newhouse, P. A., **Potter**, A., Corwin, J., & Lenox, R. (1994a). The role of nicotinic systems in the cognitive disorder of Alzheimer's disease. In *Alzheimer Disease* (pp. 191-195): Springer.
2. Newhouse, P. A., **Potter**, A., Piasecki, M., Geelmuyden, J., Corwin, J., & Lenox, R. (1995). Nicotinic modulation of cognitive functioning in humans. In *Effects of Nicotine on Biological Systems II* (pp. 345-351): Springer.
3. **Potter**, A., & Newhouse, P. A. (2002). Clinical methodologies in the examination of nicotinic effects on cognition. In *Nicotinic Receptors in the Nervous System* (pp. 261-277): CRC Press New York, NY.
4. Garavan, H., **Potter**, A. S., Brennan, K. L., & Foxe, J. J. (2015). Neural bases of addiction-related impairments in response inhibition.

#### Patents Issued or Pending

Stop Signal Task and Methodology licensed to CogState LTD. Registered through UVM Ventures and Technology Commercialization, 2011. This is a licensing agreement for the programming and analysis of the stop signal task as developed by my laboratory.

**Other Creative Activities** - none

**Quality Improvement and Patient Safety Activities** - none

#### SUMMARY OF SCHOLARLY ACTIVITIES

My accomplishments include continuous NIH grants since 2005 with over \$15 million awarded as PI. I am a Site PI for the Adolescent Brains Cognitive Development (ABCD) study, a 10-year longitudinal study of adolescent brain development funded by the NIH. ABCD is the largest study of adolescent health and development in the US. I am a recognized leader within the ABCD Consortium serving on the Council of Investigators, and as Chair of two assessment workgroups. My publication record is strong with over 60 peer-reviewed

manuscripts (h-index=25); and invited presentations both Nationally and Internationally. I am an active member of the UVM research community, serving on the Medical Sciences IRB since 2008, and as Chair of the IRB since 2018. I provide National service as an ad-hoc reviewer for scientific journals and NIH study sections, I mentor undergraduate, graduate, and medical students, as well as Post-Doctoral scholars and Jr. Faculty at UVM.

## INVITED PRESENTATIONS

<b>Regional</b>		
2013	Vermont Brain Bee Keynote Presentation, “Adolescents, Impulsivity and Brain Function”	Burlington, VT
2017	Community Lecture: Emerging results from the ABCD Study at the University of Vermont	Burlington, VT
2018	Psychiatry Grand Rounds, University of Vermont ““The Adolescent Brain Cognitive Development study: An update and initial findings”	Burlington, VT
2018	Community Rounds, UVM Medical Alumni Association, “The ABCD Study”	Burlington, VT
2019	Community Lecture: “Vermont Kids: Behavior and Brain: An Update from the ABCD Study”	
2019	Pediatric Grand Rounds, University of Vermont “Learning about Adolescent Development from the ABCD Study”	Burlington, VT
2020	Psychiatry Grand Rounds, University of Vermont “DayOne Research Update”	Burlington, VT
<b>National</b>		
2005	Symposium at the Annual Meeting, Society of Biological Psychiatry “Dysfunction of reward systems in psychopathology: Clinical and research implications”	Atlanta, GA
2011	Invited lecture at the Nicotinic Acetylcholine Receptors as Therapeutic Targets meeting. “Nicotinic Modulation of Impulsive Responding in Humans”.	Washington, DC
2013	National Institute on Drug Abuse Symposium at the Annual Meeting of the American Academy of Child and	Orlando, FL

	Adolescent Psychiatry “Understanding ADHD and Smoking”	
2016	ABCD Study Annual Meeting “Early recruitment success – lessons learned in Vermont”	San Diego, CA
2018	CDC Grand Rounds “Measuring gender in the ABCD Study”	Atlanta GA
2018	ABCD Train the Trainer: Hot Topic: How and why to measure gender in adolescence.	San Diego, CA
2018	Symposium: Big-Data Approaches to Identifying the Neurodevelopmental Trajectories of Psychiatric Illness: Novel Emerging Results from the Adolescent Brain and Cognitive Development Study. Annual Meeting American College of Neuropsychopharmacology	Hollywood, FL
2018	ABCD Annual Meeting: Using dimensional measures of gender to examine mental health in the ABCD Study.	La Jolla, CA
2019	ABCD Train the Trainer: An interactive workshop on understanding gender diversity	San Diego, CA
2020	HBCD Phase I Investigator Meeting Presentation: “Investigation of Opioid Exposure and Neurodevelopment”	Virtual
2020	ABCD Train the Trainer: Best practices in gender inclusive assessment – beyond asking pronouns.	Virtual
2021	Community Anti-Drug Coalitions of America: Mid-Year Training Institute. “Understanding risk factors among gender and sexual minority youth in the ABCD Study”	Virtual
<b>International</b>		
2010	European Society for Research on Nicotine and Tobacco “Nicotinic receptors as therapeutic targets for compromised cognitive performance in neuropsychiatric disorders”	Bath, UK
2012	European Society for Research on Nicotine and Tobacco (SRNT-E)	Helsinki, Finland

June 2017

Potter, Alexandra S.

“Nicotinic Modulation of Cognitive Function:  
Therapeutic Implications for Parkinson’s Disease”

2013

BF Skinner Lecture, Association for Behavioral  
Analysis International “Nicotinic Acetylcholine  
Receptor Function Modulates Impulsivity in ADHD:  
Clinical Implications”

Minneapolis, MN